Scenario 1 Number of first-phase subjects: 400 cases 1,200 controls | Scenario 2 Number of first-phase subjects: 1,200 cases 1,200 controls | Scenario 3 Number of first- phase subjects: 400 cases 12,000 controls | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
True OR†† | OR* | SD* | Ef** | OR* | SD* | Ef** | OR* | SD* | Ef** | |
Individual-level information on all subjects † | 1.50 | 1.49 | 0.18 | 100 | 1.50 | 0.12 | 100 | 1.50 | 0.16 | 100 |
3.00 | 3.00 | 0.17 | 100 | 3.00 | 0.11 | 100 | 3.00 | 0.14 | 100 | |
Method 1‡ | 1.50 | 1.48 | 0.25 | 53 | 1.50 | 0.24 | 25 | 1.50 | 0.25 | 43 |
3.00 | 3.01 | 0.24 | 51 | 2.98 | 0.23 | 23 | 2.99 | 0.23 | 40 | |
Method 2‡ | 1.50 | 1.60 | 0.32 | 29 | 1.56 | 0.24 | 25 | 1.59 | 0.29 | 28 |
3.00 | 3.05 | 0.27 | 39 | 3.01 | 0.18 | 39 | 3.04 | 0.24 | 37 | |
Method 3‡ | 1.50 | 1.49 | 0.24 | 58 | 1.50 | 0.22 | 29 | 1.50 | 0.24 | 46 |
3.00 | 3.00 | 0.22 | 59 | 2.98 | 0.21 | 29 | 3.00 | 0.21 | 47 | |
Method 4‡ | 1.50 | 1.49 | 0.19 | 81 | 1.50 | 0.20 | 37 | 1.51 | 0.19 | 68 |
3.00 | 2.99 | 0.16 | 78 | 3.01 | 0.17 | 44 | 3.02 | 0.18 | 66 |